Troubled health care roll-up artist Valeant is like a bunch of “choir boys” when compared pharmaceutical concern Mallinckrodt, short seller Andrew Left of Citron Research said on CNBC Wednesday after the close, where he was confronted by the firm’s CEO.
Left was short and vocal regarding Valeant, says its the tip of the iceberg
Left is among a group of highly watched researchers who is perhaps best known for his short selling recommendations, particularly with regard to Valeant Pharmaceuticals. Left had talked the stock down before buying back his exposure.
On October 2, ValueWalk reported on a Citron research piece that claimed “Valeant’s business model...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
